ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly royalty revenue ($M) [reported separately through FY2023] ($M)
Form 10-K Disaggregated Revenue Note (through FY2023)
Latest, Q4 2023
105
Period ended Dec 31, 2023
Change on a year earlier
+222.5%
32.5 in Q4 2022
History
27 quarters
Since Q2 2017
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Royalty revenue ($M) [reported separately through FY2023] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 105 | +222.5% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 31.3 | -27.7% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 30.3 | -11.9% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 25.1 | -52.8% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 32.5 | -16.5% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 43.3 | -30.3% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 34.4 | +11.0% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 53.2 | +23.7% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 38.9 | +14.1% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 62.1 | +97.1% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 31 | -10.7% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 43 | +21.5% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 34.1 | -75.4% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 31.5 | -53.6% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 34.7 | -41.8% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 35.4 | -0.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 139 | +219.9% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 67.9 | -10.9% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 59.6 | -55.4% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 35.5 | -29.1% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 43.3 | +9.9% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 76.2 | +107.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 134 | +281.7% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 50.1 | – | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 39.4 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 36.7 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 35 | – | Form 10-Q (filed 2018-07-25) ↗ |
Cite this data
StockData. (2026). Eli Lilly Royalty revenue ($M) [reported separately through FY2023] ($M), quarterly Q2 2017–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev_royalty_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.